Search

Displaying results 3821 - 3830 of 10000 in total
  1. Pathway

    Cardiolipin Biosynthesis CL(10:0/20:0/20:0/20:0)

    smpdb.ca/view/SMP0178969
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  2. Pathway

    Cardiolipin Biosynthesis CL(13:0/20:0/20:0/20:0)

    smpdb.ca/view/SMP0195819
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  3. Pathway

    Cardiolipin Biosynthesis CL(16:0/20:0/20:0/20:0)

    smpdb.ca/view/SMP0206912
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  4. Drug

    Methyprylon

    go.drugbank.com/drugs/DB01107
    ApprovedIllicitWithdrawn

    Methyprylon was withdrawn from the U.S. market in June 1965 and the Canadian market in September 1990 due to adverse events.

  5. Drug

    Moxisylyte

    go.drugbank.com/drugs/DB09205
    Approved

    Moxisylyte, denominated as thymoxamine in the UK, is a specific and orally active α1-adrenergic antagonist. … [L1172] This drug was developed by the Japanese company Fujirebio and also by the American company Iolab in the late 80s.

    Categories: Drugs Used in Erectile Dysfunction
  6. Drug

    LU-31130

    go.drugbank.com/drugs/DB05828
    Experimental

    It acts at the Dopamine D4 receptors in the cortex and has low affinity for D2 receptors, adrenoceptors, muscarinic and histaminergic receptors. … LU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders.

  7. Drug

    V-SARS

    go.drugbank.com/drugs/DB15812
    Investigational

    Immunitor Inc., the sponsor, is currently testing this oral vaccine for immunogenicity in 20 healthy volunteers in a Phase 1 clinical trial (NCT04380532).

  8. Drug

    Clopenthixol

    go.drugbank.com/drugs/DB13841
    Investigational

    It is an antagonist at D1 and D2 dopamine receptors.

  9. Drug

    Pomaglumetad methionil

    go.drugbank.com/drugs/DB05096
    Investigational

    LY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. … Further studies are planned or are ongoing to learn more about the safety and effectiveness, including determining an optimal therapeutic dose for LY2140023.

  10. Drug

    Influenza A virus A/Singapore/INFIMH-16-0019/2016 IVR-186 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB14560
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: VAXİGRİP 0,5 ML IM/SC ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR , 10 ADET, VAXİGRİP TETRA 0,5 ML IM/SC ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR , 1 ADET